Protalix BioTherapeutics, Inc.
PLX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $136 | $120 | $66 | $37 |
| - Cash | $20 | $24 | $17 | $39 |
| + Debt | $6 | $28 | $33 | $33 |
| Enterprise Value | $122 | $124 | $83 | $31 |
| Revenue | $53 | $65 | $48 | $38 |
| % Growth | -18.5% | 37.5% | 24.2% | – |
| Gross Profit | $29 | $43 | $28 | $22 |
| % Margin | 54.5% | 64.9% | 58.9% | 57.4% |
| EBITDA | $7 | $13 | -$11 | -$19 |
| % Margin | 12.2% | 19.8% | -22.6% | -49.4% |
| Net Income | $3 | $8 | -$15 | -$28 |
| % Margin | 5.5% | 12.7% | -31.3% | -71.9% |
| EPS Diluted | 0.037 | 0.1 | -0.31 | -0.62 |
| % Growth | -63.4% | 132.3% | 50% | – |
| Operating Cash Flow | $9 | -$1 | -$25 | -$10 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$1 |
| Free Cash Flow | $7 | -$2 | -$26 | -$12 |